Efter 6 måneders terapi var der en signifikant smertereduktion hos de Replagal- behandlede patienter sammenlignet med placebo (p=0, 021) bedømt ud fra Brief Pain Inventory (en valideret skala til måling af smerte).
After 6 months of therapy there was a significant reduction in pain in the Replagal treated patients compared with placebo (p=0.021), as measured by the Brief Pain Inventory (a validated pain measurement scale).